Valuation: Mesoblast Limited

Market Cap 2.44B 1.72B 1.54B 1.43B 1.29B 2.41B 164B 17.04B 6.79B 85.65B 6.45B 6.31B 272B P/E 2027 *
-79.7x
P/E 2028 * 19.9x
Enterprise Value 2.55B 1.79B 1.61B 1.49B 1.35B 2.51B 171B 17.77B 7.08B 89.3B 6.72B 6.58B 284B EV / Sales 2027 *
9.99x
EV / Sales 2028 * 6.21x
Free-Float
63.88%
Yield 2027 *
-
Yield 2028 * -
1 day+1.35%
1 week+6.82%
Current month-10.90%
1 month-12.96%
3 months-12.15%
6 months-12.15%
Current year-30.88%
1 week 1.76
Extreme 1.755
1.95
1 month 1.74
Extreme 1.735
2.16
Current year 1.74
Extreme 1.735
3.31
1 year 1.74
Extreme 1.735
3.31
3 years 0.26
Extreme 0.255
3.37
5 years 0.26
Extreme 0.255
3.37
10 years 0.26
Extreme 0.255
5.7
Manager TitleAgeSince
Chief Executive Officer 69 23/03/2011
Director of Finance/CFO 59 17/11/2025
Chief Tech/Sci/R&D Officer - 11/03/2026
Director TitleAgeSince
Director/Board Member 69 01/01/2007
Director/Board Member 75 15/04/2013
Director/Board Member 79 06/03/2014
Date Insider Type Main position Quantity % Market Cap. Importance
8/19/26 A Free

Director

875,000 0.0674%
7/17/26 A Exercice

Founder

1,885,334 0.1456%
7/17/26 A Exercice

Founder

-1,885,334 0.1456%
Change 5-day change 1-year change 3-year change Capi.($)
+1.35%+6.82%-26.56%+415.07% 1.69B
+0.65%-3.56%+33.53%+60.50% 63.48B
+1.76%+1.27%+11.82%+82.12% 54.55B
-0.94%+0.99%+10.45%+102.18% 53.59B
+2.42%+0.56%+27.53%+57.02% 44.75B
+2.25%-3.17%+18.10%+100.52% 41.62B
+0.17%-4.02%+220.56%+916.19% 39.91B
+0.64%-3.85%+11.71%+45.57% 32.47B
+29.06%+47.63%+107.12%+94.27% 26.7B
+3.72%-7.45%+24.25%-2.99% 23.36B
Average +4.10%+0.16%+43.85%+187.05% 38.21B
Weighted average by Cap. +3.08%-0.26%+46.80%+161.54%

Financials

2027 *2028 *
Net sales 255M 179M 161M 149M 135M 252M 17.08B 1.78B 709M 8.94B 673M 659M 28.38B 416M 293M 263M 243M 220M 411M 27.9B 2.91B 1.16B 14.6B 1.1B 1.08B 46.35B
Net income -26.28M -18.5M -16.6M -15.34M -13.9M -25.96M -1.76B -183M -73.07M -922M -69.41M -67.95M -2.93B 105M 73.68M 66.1M 61.12M 55.35M 103M 7.02B 731M 291M 3.67B 276M 271M 11.66B
Net Debt 104M 73.26M 65.73M 60.77M 55.03M 103M 6.98B 727M 289M 3.65B 275M 269M 11.59B 143M 101M 90.37M 83.55M 75.67M 141M 9.59B 999M 398M 5.02B 378M 370M 15.94B
Projected Income Statement - Annual - Mesoblast Limited
Logo Mesoblast Limited
Mesoblast Limited is an Australia-based biotechnology company. The Company is engaged in developing allogeneic (off-the-shelf) cellular medicines for the treatment of severe and life-threatening inflammatory conditions. The Company has developing a range of late-stage product candidates, derived from its first and second generation proprietary mesenchymal lineage cell therapy technology platforms therapies for distinct indications. The Company's Ryoncil (remestemcel-L-rknd) is an allogeneic bone marrow-derived mesenchymal stromal cell (MSC) therapy. Its other product candidate is Revascor (rexlemestrocel-L). Rexlemestrocel-L is second generation mesenchymal lineage precursor cell product platform and is in late-stage development for treatment of: Chronic heart failure (CHF) and Chronic low back pain (CLBP) due to degenerative disc disease. The two products have been commercialized in Japan and Europe by the Company's licensees.
Employees
108
Date Price Change Volume
28/10/26 A$1.880 +1.35% 2,650,500
27/10/26 A$1.855 +3.92% 3,071,957
26/10/26 A$1.785 +0.56% 1,315,866
23/10/26 A$1.775 -3.01% 2,164,966
22/10/26 A$1.830 -1.61% 3,004,349
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
BB
MarketScreener Ratings - Mesoblast Limited
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
5
Last Close Price
1.880AUD
Average target price
3.573AUD
Spread / Average Target
+90.07%

Quarterly revenue - Rate of surprise

Rate of surprise - Net sales - Quarterly - Mesoblast Limited